GlobeNewswire·Nov 12, 2026, 4:15 PM ET

Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Immix Biopharma reported an 89% complete response rate for all 45 patients in the NEXICART-2 trial, with MRD-negativity suggesting a potential future complete response rate of up to 98%.
Interim data from the NXC-201 NEXICART-2 trial was selected for oral presentation at the 68th ASH Annual Meeting in New Orleans on December 14, 2026.
The company is advancing commercial launch readiness through site activation, provider & payer engagement, manufacturing activities, & healthcare professional education.
Immix plans to submit a Biologics License Application (BLA) in mid-2027 & initiate the NEXICART-3 front-line trial in the first half of 2027.
Dr. David He was appointed Senior Vice President, Head of Technical Operations to lead chemistry, manufacturing, & controls.
Karin McIntosh was appointed Senior Vice President, Head of Regulatory Affairs to lead global regulatory affairs.
Additional key team members were hired across commercial, regulatory, quality, medical affairs, & medical science liaison functions.
Immix will present at the 45th Annual J.P. Morgan Healthcare Conference in San Francisco from January 11-14, 2027.
As of September 30, 2026, Immix held $340.9 million in cash, cash equivalents, & marketable securities, providing an operating runway into mid-2028.
Operating expenses for the third quarter ended September 30, 2026, totaled $15.9 million.